- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Comparison
- Forums
- Visit our forums
- Jobs
- Visit our job site
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire New!
- Contact us
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
is a division of
Stay current with the latest press releases from within the industry.
Alcon's AcrySof® ReSTOR® Apodized Diffractive Aspheric Intraocular Lens Approved by FDA
Release issued 1st February 2007
| Alcon's AcrySof® ReSTOR® Apodized Diffractive Aspheric Intraocular Lens Approved by FDA |
| FORT WORTH, Texas, Feb 01, 2007 (BUSINESS WIRE) -- Alcon Laboratories, Inc., a subsidiary of Alcon, Inc. (NYSE:ACL), announced today that the U.S. Food and Drug Administration (FDA) has granted approval of the AcrySof® ReSTOR®apodized diffractive aspheric intraocular lens for the visual correction of aphakia following cataract surgery in adult patients with and without presbyopia. The AcrySof® ReSTOR®apodized diffractive aspheric intraocular lens is the only FDA-approved presbyopia-correcting intraocular lens that incorporates aspheric optics into its design. Alcon will begin a phased commercial launch of this new lens after necessary consignment quantities are established, with full distribution expected by the middle of the year. About Alcon Alcon, Inc. is the world's leading eye care company with sales of $4.4 billion in 2005. Alcon, which has been dedicated to the ophthalmic industry for more than 60 years, develops, manufactures and markets pharmaceuticals, surgical equipment and devices, contact lens care solutions and other vision care products that treat diseases, disorders and other conditions of the eye. For more information on Alcon, Inc., visit the Company's Web site at www.alcon.com. Caution Concerning Forward-Looking Statements. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, relating principally to our ability to successfully market and sell the AcrySof®ReSTOR® apodized diffractive aspheric intraocular lens for cataract surgery. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by our forward-looking statements. These statements reflect the views of our management as of the date of this press release with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. You should read this press release with the understanding that our actual future results may be materially d ifferent from what we expect. Except to the extent required under the federal securities laws and the rules and regulations promulgated by the Securities and Exchange Commission, we undertake no obligation to publicly update or revise any of these forward-looking statements, whether to reflect new information or future events or circumstances or otherwise. SOURCE: Alcon, Inc. Alcon, Inc. |
Company details
If you want to find out more about the company visit Alcon profile.
Latest Alcon press releases
(23rd January 2008) Alcon Recognized as One of the '100 Best Companies to Work For' by FORTUNE Magazine for 10th Consecutive Year
(6th November 2007) Alcon Gains All Regulatory Clearances for Acquisition of WaveLight AG
(31st July 2007) Alcon's Treatment of Glaucoma and Ocular Hypertension, TRAVATANZTM Solution, Approved in Japan
(26th February 2007) Leading Scientists Honored for Outstanding Ophthalmic Research
(18th September 2006) Alcon Licenses Novel Anti-Infective Compounds for Eye, Ear and Sinus Infections from NovaCal
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us